Literature DB >> 28769432

IMMUNOLOGICAL MONITORING IN TRANSPLANTATION.

G S Chopra1, J R Bhardwaj2, N K Mehra3, S C Dash4.   

Abstract

Sixty eight patients who had undergone live related donor renal transplantation (LRD), were evaluated for soluble interleukin-2 receptors (sIL-2R), tumour necrosis factor alpha (TNF-α) and autoantibodies against IgG(Fab')2 and IgG(Fc), at pre- and various post-transplant intervals. Serum sIL-2R levels were significantly elevated in hemodialysed patients awaiting transplantation (mean 259.2 ± 90.5 pmol/L) as compared to healthy volunteers (mean 52.6 ± 16.7 pmol/L). In 96 samples obtained from patients with well-functioning grafts (WFG), the post-transplant sIL-2R levels (135.6 ± 65.4 pmol/L) were significantly lower (p < 0.001) than their pretransplant values. Eight patients with cyclosporin-A (CsA) nephrotoxicity, 14 with reversible acute tubular necrosis (ATN) and 4 patients with partial surgical obstruction, revealed moderate levels (99.0 ± 13.7, 184.1 ± 47.5, 156.7 ± 40.4 pmol/L respectively). On the other hand, 29 patients with acute rejection episodes, 11 with chronic rejection and 8 with infections had significantly higher levels (307.9 ± 89.3, 253.3 ± 68.6,345 ± 110.6 pmol/L), (p < 0.001). TNF-α levels were also raised in rejection and infective episodes but were not statistically significant. Serum anti-IgG(Fab')2 levels were found higher (0.407 OD) in WFG as compared to those with declining graft functions (0.279 OD). On the contrary high pre- and post-transplant anti-IgG(Fc) activity was associated with increased graft rejection and lower survival rate.

Entities:  

Keywords:  Autoantibodies; Immunoglobulins; Interleukin-2; Kidney transplantation; Receptors; Transplantation immunology; Tumor necrosis factor

Year:  2017        PMID: 28769432      PMCID: PMC5530838          DOI: 10.1016/S0377-1237(17)30642-1

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  8 in total

1.  The association of kidney graft outcome with pretransplant serum IgG-anti-F(ab')2 gamma activity.

Authors:  C Süsal; J Groth; H H Oberg; P Terness; G May; G Opelz
Journal:  Transplantation       Date:  1992-10       Impact factor: 4.939

2.  Interleukin-1 beta and tumor necrosis factor-alpha serum levels in renal allograft recipients.

Authors:  L N Bubnova; A Kabakov; N Serebrianaya; S Ketlinky
Journal:  Transplant Proc       Date:  1992-12       Impact factor: 1.066

3.  MICRODROPLET ASSAY OF HUMAN SERUM CYTOTOXINS.

Authors:  P I TERASAKI; J D MCCLELLAND
Journal:  Nature       Date:  1964-12-05       Impact factor: 49.962

4.  Usefulness of serum interleukin 2 receptor levels in renal allograft recipients.

Authors:  J J Plaza; G Blum; A Ortiz; L Hernando; E Feijoo; J Sanz; R Garcia; J Egido; F Ortiz
Journal:  Transplant Proc       Date:  1992-02       Impact factor: 1.066

5.  Soluble CD23 and interleukin-2 receptor levels in renal allograft recipients.

Authors:  M Beksaç; K Dalva; F Gönenç; I Dalva; S Gariboğlu; N Batur; S Cetin
Journal:  Transplant Proc       Date:  1993-04       Impact factor: 1.066

Review 6.  Cytokines and transplantation.

Authors:  J P Soulillou
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

7.  Immunologic parameters for the diagnosis of graft rejection.

Authors:  C Hammer; H Reichenspurner; G Klima
Journal:  Transplant Proc       Date:  1993-08       Impact factor: 1.066

8.  Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha.

Authors:  A Herbelin; A T Nguyen; J Zingraff; P Ureña; B Descamps-Latscha
Journal:  Kidney Int       Date:  1990-01       Impact factor: 10.612

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.